Appointments RAJ Devices May/June 2006
This article was originally published in RAJ Devices
The US Food and Drug Administration (FDA) has announced the appointment of David Boyer as assistant commissioner for legislation. Mr Boyer will oversee the drafting of congressional testimony, respond to congressional enquiries and assist in the development of public health legislation. He will work closely with the Office of the Commissioner, as well as the six FDA centres. Mr Boyer has previously held senior positions at the Department of Health and Human Services (HHS), most recently that of special assistant for oversight in the office of the Assistant Secretary for Legislation. He joins the FDA from this role. Previous jobs have included director of federal government relations for the Biotechnology Industry Organization. Mr Boyer replaces Patrick Ronan, who becomes the FDA's chief of staff.
You may also be interested in...
An EU guideline on the methodological aspects of pharmacoepidemiology has been updated to promote collaboration by researchers on high-quality, multi-centre observational studies in the context of COVID-19.
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.
New chief medical officers take up positions at Abeona Therapeutics, Akcea Therapeutics and Oncologie, while there are new CFOs at Affimed, NGM Biopharmaceuticals, Phathom Pharmaceuticals, Oncologie and Syndax Pharmaceuticals.